 FOSTER CITY, Calif., June 13, 2021 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis NASH and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET 5:30 a.m. PT to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with NASH. Webcast and conference call details are as follows: 